ArticleTranslational oncology2025
Dual action of pyrimidine derivatives: Targeting tamoxifen resistance in breast cancer.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of EMT in drug resistance of breast cancer: molecular mechanisms and therapeutic strategies.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionApproximately 70 % of patients with breast cancer (BC) have estrogen receptor (ER)-positive tumors. Endocrine therapy is the principal treatment for these patients. Tamoxifen (TAM), a selective ER modulator, is commonly administered to premenopausal patients with ER-positive BC. However, resistance to TAM poses a major clinical hurdle as TAM-resistant BC cells often show increased proliferation and motility as well as undergo epithelial-mesenchymal transition (EMT).
objectivePyrimidine-based small molecules were reported as both nuclear factor kappa B (NF-κB) and Wnt/β-Catenin pathway regulators. This report discovered oxazine (TRX-01) linked pyrimidine as an inhibitor of NF-kB and triazole (TTP-5) linked pyrimidine as an inhibitor of Wnt/β-Catenin signaling in TAM-resistant MCF-7 breast cancer cells (MCF-7R).
methodsColony formation, wound healing, and Transwell assays were conducted to assess cell migration and invasion. MTT assay was used to evaluate cytotoxic effects. Western blotting was used to determine the signaling mechanisms for NF-κB and EMT phenotypes. Xenograft models were utilized to examine the in vivo effectiveness of TRX-01.
resultsTRX-01 reversed TAM resistance in MCF-7R cells, whereas TTP-5 reduced the motility of MCF-7R cells. Additionally, TRX-01 inhibited the activation of the NF-κB signaling pathway in MCF-7R cells, whereas TTP-5 inhibited the EMT-like phenotype of MCF-7R cells by impairing the activation of Wnt/β-catenin signaling. The differences in the functions of the two pyrimidine structures are attributed to their additional structures bearing both TRX-01 and TTP-05.
conclusionPyrimidine-based TRX-01 and TTP-5 lead structures are promising agents for inhibiting the progression of TAM-resistant breast cancer cells. These results support the need for additional comprehensive in vivo and clinical studies to confirm the efficacy and safety of these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.